



OvaSuiteSM

Confidently Move from Assessment to Action

A portfolio of blood tests developed to assess the risk of ovarian cancer in any women with an adnexal mass



Adnexal masses present a unique diagnostic dilemma.

For the first time, healthcare providers have a set of blood tests that — when combined with their clinical experience, ultrasound, and the patient’s history — allow them confidently develop a medical management plan and include the right specialists at the right time.

OvaSuiteSM risk assessment tests offer the following to healthcare providers and their patients:

- Enhanced provider confidence in the chosen medical management plan
- Efficient triaging of specialist referrals for only higher risk patients
- Reduced patient anxiety through improved information about malignancy risk
- Avoidance of potentially unnecessary or premature surgeries

The OvaSuite portfolio of blood tests applies proprietary algorithms incorporating patient features (such as menopausal status) and the levels of up to 7 biomarkers in the blood.

Protein	Apolipoprotein A1	B2 Microglobulin	CA 125	Prealbumin	Transferrin	HE4 (Human Epididymis protein 4)	FSH (Follicle Stimulating Hormone)
Function	Cholesterol transport	Host immune response	Released by tumor cells	Hormone and vitamin transport	Iron transport	Released by tumor cells	Hormone regulation

In addition to the score and ovarian cancer risk assessment, the report will include the CA 125 result, and when appropriate, the HE4 result.

OvaWATCHSM OvaWatchSM is intended to assist in assessing the risk of ovarian cancer when a healthcare provider’s initial clinical assessment indicates that an adnexal mass is either indeterminate or benign.

A Negative Predictive Value of over 99% gives providers confidence in a low probability of malignancy for **both** premenopausal and postmenopausal patients.¹ A lower risk score provides reliable clinical data to further support a clinician’s plan to manage and monitor. A higher score does not indicate the presence of cancer; rather, it provides information that may assist the clinician in considering additional clinical assessment, consultation, or surgery.

Ova1^{plus} Ova1Plus[®] is intended to assist in determining the right surgical plan for women with adnexal masses.

Understanding a patient’s risk for ovarian cancer where surgery has been scheduled but not yet undertaken ensures the patient receives the right surgery at the right time and by the right provider, potentially reducing the overall risk of unexpected surgical complications.

Ova1Plus is the combination of two FDA-cleared tests for women with pelvic masses that are planned for surgery. Ova1[®] is performed first, leveraging its high sensitivity of 96% with clinical assessment.² Overa[®], with a specificity of 69%, is automatically performed when an intermediate risk is detected.³ Combining Ova1 & Overa leads to a highly sensitive and clinically useful risk assessment.

OvaSuite: One blood draw for all women with an adnexal mass

Whether a healthcare provider is performing an initial clinical assessment or planning for surgery, OvaSuite has a tool to help them confidently develop a management plan for all points along the healthcare journey. These results, when combined with the provider's judgment, imaging and patient history, provide better clinical insight over the single biomarker tests used in the past.

Pelvic Mass Detected Ovarian Cancer Risk Assessment Needed

Clinical Management



For adnexal masses evaluated by initial clinical assessment as indeterminate or benign

Low Probability of Malignancy

- Ongoing mass monitoring
- Additional clinical procedure

Indeterminate

- Consultation with specialist
- Possible surgical management

Surgical Management



For adnexal masses planned for surgery



Low Risk

Automatic Reflex



Low Risk

- Clinical management
- Proceed with surgical plan

Elevated Risk

- Consultation with specialist
- Referral to gynecologic oncologist

Our commitment to providers and patients:

- Rapid turnaround — usually within 72 hours
- Easy to read reports with the risk score and results of relevant individual biomarkers (CA 125, HE4)
- Clinical experts with OvaSuite experience to aid in the interpretation of results
- Experienced, responsive field and customer service team

Price Transparency and Financial Assistance:

Aspira Women's HealthSM is committed to making our tests available to all women who need it. An insured patient's out-of-pocket cost is limited to their co-payment/deductible. Uninsured patients are billed a reasonable patient pay amount. We offer financial assistance and payment plans for patients who qualify, and are covered by Medicare and Medicaid in many states.

Utilize the OvaSuite portfolio of products and confidently move from assessment to action.

A single blood draw — which can be performed at a number of national and regional laboratories or in a healthcare provider's office using our proprietary testing kit — is all that is needed.



To learn more, order kits, or to locate one of our phlebotomy partners, reach out to your Aspira Women's Health Sales Representative, or contact Aspira Women's Health Customer Service at **844-277-4721** or **aspirasupport@aspirawh.com**.

◀ [scan here to learn more](#)

References

1. Analytical Validation of a Deep Neural Network Algorithm for the Detection of Ovarian Cancer. Reilly G, Bullock R, Greenwood J, Ure DR, Stewart E, Davidoff P, DeGrazia J, Fritsche H, Dunton CJ, Bhardwaj N, and Northrop LE. *JCO Clin Cancer Inform* 6:e2100192. 2022
2. Bristow, R. E., Smith, A., Zhang, Z., Chan, D. W., Crutcher, G., Fung, E. T., & Munroe, D. G. (2013). Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. *Gynecologic oncology*, 128(2), 252-259.
3. Dunton, C. J., Bullock, R. G., Fritsche, H. A., & Twiggs, L. B. (2020). Improvement in MIA (OVA1) testing for detection of ovarian malignancy. *Gynecologic Oncology*, 159, 25.

PRECAUTION: Ova1[®] and Overa[®] should not be used without an independent clinical and imaging evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

📞 **844.277.4721** | ✉ **aspirasupport@aspirawh.com**

© 2022 Aspira Women's Health. All rights reserved. The Aspira Women's Health, OvaSuite, Ova1, Ova1Plus, Overa, and OvaWatch logos are registered trademarks of Aspira Women's Health in the U.S. and other countries. Aspira Women's Health reserves the right to change this document at any time without notice and disclaims liability for editorial, pictorial or typographical errors.



Transforming women's gynecological health, starting with ovarian cancer